Bio logo

People  |   Products   |   Projection

Bio Integrates 2022 Draft Agenda

LONDON, 17 MAY 2022

PANEL DISCUSSIONS AND WORKSHOPS

PLEASE NOTE The agenda and timings have not been finalised so maybe subject to change.

DELEGATES WILL BE FREE TO CHOOSE FROM TRACK 1, 2 or 3 AT ANY TIME.

Welcome

Welcome

Opening

Opening Remarks

Fireside Chat

Fireside Chat

PEOPLE

How do we assemble and accelerate our teams for succes?

PRODUCTS

How do we protect, progress and pivot our products for maximal value?

PROJECTION

What does the future hold for life science investment, intellect and infrastructure?

Session 1

Living on the edge

With tech and biotech converging, how can we innovate and collaborate across the sector edges?

Money, money, money

Early stage funding is always a rate-limiting step in product develop. How can we access EU grant funding, and what is the UK doing to plug the gap in non-dilutive funding?

Go big or go home

The Government’s Industrial Strategy and commitment to life science funding relies on companies scaling their science in the UK. How do you scale for success?

Session 2

The C word

The culture within an organisation can be its success or downfall. How do we build management teams and leadership structures to create an inspiring company culture?

Protect at all costs

The costs of protecting your IP can ramp up rapidly. How can you plan your IP strategy efficiently and cost-effectively?

Put yourself in my place

With the clinical regulatory landscape evolving across the UK and EU, should we be making the UK the go to place for Phase I clinical studies?

Session 3

Girls just wanna have fun(ds)

Less than 5% of investment goes to female-led businesses. What are we doing to address the gender investment gap?

Get out(sourced)!

Finding the right outsourcing partners to help develop and scale your products is critical to milestones and budgets. How can we ensure we are working with the right partners at the right time?

Survive or thrive

What skills do you need to survive and thrive in the high pressure biotech environment?

Session 4

Transfer targets

Tech transfer departments in Universities are inundated with potential translational science. How do they select the projects to back?

Pivoting your products

When initial target indications or markets are no longer feasible, it is critical to pivot your products rapidly. How do we plan for pivoting to give minimal disruption and maximum success?

Brain drain or brain gain

Many predicted that Bexit would cause a brain drain. Has this materialised or are we seeing more gain than drain?

Session 5

Where you lead

Selecting your lead investors and assembling your syndicate is pivotal to the success of a biotech. Do you pick your investors, or do they pick you?

Pitch perfect

A series of pitches from emerging biotechs.

Economies of scale

Do we have the infrastructure to enable and encourage biotechs to scale their businesses in the UK?

Closing

Closing remarks

Welcome

Opening Remarks

Fireside Chat

PEOPLE

How do we assemble and accelerate our teams for succes?

Session 1:

Living on the edge

With tech and biotech converging, how can we innovate and collaborate across the sector edges?

Session 2:

The C word

The culture within an organisation can be its success or downfall. How do we build management teams and leadership structures to create an inspiring company culture?

Session 3:

Girls just wanna have fun(ds)

Less than 5% of investment goes to female-led businesses. What are we doing to address the gender investment gap?

Session 4:

Transfer targets

Tech transfer departments in Universities are inundated with potential translational science. How do they select the projects to back?

Session 5

Where you lead

Selecting your lead investors and assembling your syndicate is pivotal to the success of a biotech. Do you pick your investors, or do they pick you?

Closing Remarks

 

PRODUCTS

How do we protect, progress and pivot our products for maximal value?

Session 1:

Money, money, money

Early stage funding is always a rate-limiting step in product develop. How can we access EU grant funding, and what is the UK doing to plug the gap in non-dilutive funding?

Session 2:

Protect at all costs

The costs of protecting your IP can ramp up rapidly. How can you plan your IP strategy efficiently and cost-effectively?

Session 3:

Get out(sourced)!

Finding the right outsourcing partners to help develop and scale your products is critical to milestones and budgets. How can we ensure we are working with the right partners at the right time?

Session 4:

Pivoting your products

When initial target indications or markets are no longer feasible, it is critical to pivot your products rapidly. How do we plan for pivoting to give minimal disruption and maximum success?

Session 5:

Pitch perfect

A series of pitches from emerging biotechs.

Closing Remarks

PROJECTION

What does the future hold for life science investment, intellect and infrastructure?

Session 1:

Go big or go home

The Government’s Industrial Strategy and commitment to life science funding relies on companies scaling their science in the UK. How do you scale for success?

Session 2:

Put yourself in my place

With the clinical regulatory landscape evolving across the UK and EU, should we be making the UK the go to place for Phase I clinical studies?

Session 3:

Survive or thrive

What skills do you need to survive and thrive in the high pressure biotech environment?

Session 4:

Brain drain or brain gain

Many predicted that Bexit would cause a brain drain. Has this materialised or are we seeing more gain than drain?

Session 5:

Economies of scale

Do we have the infrastructure to enable and encourage biotechs to scale their businesses in the UK?

Closing Remarks

Sign up for life science integrates news

Get the latest news and updates by signing up today.

By signing up to the life science integrates newsletter, you have read and agree to our Privacy Policy, including our Cookie use.

Bio logo

People  |   Products   |   Projection

LONDON, 17 May 2022